Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
about
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsMelanoma: oncogenic drivers and the immune systemCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetTargeting BCL2-Proteins for the Treatment of Solid TumoursThe BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsAsbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathwaysSystems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsRole for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell lineClinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.CAML regulates Bim-dependent thymocyte death.BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimApoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimSAntitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cellsNoxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cellsSelumetinib produces a central core of apoptosis in breast cancer bone metastases in miceSMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumorsThe essential role of evasion from cell death in cancer.BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelDestruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells.The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country.BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.Bim and Bmf in tissue homeostasis and malignant disease.Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.BH3-only proteins in apoptosis at a glanceThe BCL-2 protein family, BH3-mimetics and cancer therapy.STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.Radiosensitization and downregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition of mitogen/extracellular signal-regulated kinase (MEK) in malignant melanoma cells.miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusBCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
P2860
Q24306326-B0D9217B-5F16-4EEF-99BF-8329CA041C5AQ26775598-9E40EF1A-2ADE-4895-82CF-6C9203B621EDQ26799864-3B4C749E-F9CE-45F8-93AB-7BD45A439505Q26853686-6D23A423-CCC1-48D4-81FD-1950A3DD8A06Q27010154-B042F49E-ECF3-40AC-81CB-E5920211E45CQ28393611-B71032C8-D9AD-4E02-8684-EB806D26ADEEQ30549646-9AB3668D-CB4F-43DC-85BB-1AE38AC4BEABQ33788708-1C2F3B67-BE9D-4523-A5A1-66EAEBA2A0CFQ33808800-C20E7287-E57A-4F29-B433-5DAB49FE3B41Q33825096-6163E673-F616-4FC8-B33B-8F6F73487DBFQ33830911-D4D5DFB9-B0E0-4F7D-A3C5-7FCD42E3B2C2Q33931340-5A46A389-9AEF-4BD5-94F6-3D7395C3BCC7Q33934591-3C9D938A-A9CD-4E8B-8074-FC19373E6E6CQ34450473-8DC687F7-BE01-45D3-9A88-A96975760CE0Q34545490-D33BACBD-2AFD-4980-BF9C-1BE241BDE328Q34786462-10DAF65A-B22E-4E47-AFA2-56098D192721Q34957229-C233157E-B0E0-44E9-9155-87E90557EA92Q35004008-1BF05880-39F1-4FDA-9B3F-56557A631BE4Q35035656-97BE1DC3-E4B4-4EE0-B45D-0722EFC19F64Q35083049-27324FC7-200F-4820-868B-82D81767D7C7Q35090029-FF75FA11-A0CB-4689-A9F6-D32EE070DEC0Q35102284-A87C3036-A518-410A-9E47-F2EF9CAAE898Q35180339-FEBF184D-612D-447D-A2AE-DA19BB16B1FEQ35536735-383059F5-3566-494D-833D-9B39C91B95B1Q35588268-650D371E-E2A8-48D1-B65C-1C33438A6142Q35678266-212A69EB-633B-4C66-B576-F463C02B3014Q35737865-EF72C13F-79AF-4B40-80BD-171BBC1DD44EQ35779325-D1C3E307-6A5F-44C0-A76C-41298253C548Q35799771-F902D0C3-5782-4910-9773-220AE4CCBBEFQ35834635-90A6A7C2-5252-4D9D-A0B4-742BCD849495Q35883875-9ACBA511-C54B-4C08-89A2-229C3638F833Q36067778-BF9780E8-09A7-456A-BC5B-D3CDDD340706Q36083385-30C505E3-5F1A-4D6C-BA08-EF940D93292BQ36199633-DBAF9A1C-03C6-4297-9794-3230753B475BQ36232000-38ABE93C-BC9F-4399-BD19-7430CB21A504Q36291106-53B85405-252C-4050-A888-EE383B9BB19CQ36507554-5D0F7958-5A7D-4512-BDF6-8822D1BCA95FQ36546429-EF42DF39-C285-454B-93A7-37FC18F35E6DQ36560775-CD5DCE37-9145-4135-9A58-EA4F863AFBC5Q36692818-50E121CA-750C-4E6F-973C-7D51DE01D022
P2860
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Treatment of B-RAF mutant huma ...... is enhanced by a BH3 mimetic.
@en
type
label
Treatment of B-RAF mutant huma ...... is enhanced by a BH3 mimetic.
@en
prefLabel
Treatment of B-RAF mutant huma ...... is enhanced by a BH3 mimetic.
@en
P2093
P2860
P356
P1476
Treatment of B-RAF mutant huma ...... is enhanced by a BH3 mimetic.
@en
P2093
Claire Harris
Clare L Scott
Elisa S Jansen
Michele Cook
P2860
P304
P356
10.1172/JCI35437
P407
P577
2008-10-23T00:00:00Z